title: 1H-magnetic resonance spectroscopic observation of cultured malignant cells pharmacologically induced to different phenotypes.
abstract: OBJECTIVE
  We evaluated the 1H nuclear magnetic resonance spectra of malignant cells after the administration of drugs that cause morphologic changes.
  
  
  METHODS
  1H spectra of a human lung adenocarcinoma cell line cultured with interferon gamma, dexamethasone, or sodium butyrate were obtained. The peaks were assigned by two-dimensional homonuclear Hartmann-Hahn spectroscopy spectra of the cells and their perchloric acid extracts. Differential spectra were used to evaluate relative changes in the peaks.
  
  
  RESULTS
  In the control culture, choline/phosphocholine peaks were increased in the cell-growth phase, and the 1.26-ppm peak was increased in the confluent state. Treatment by interferon gamma and dexamethasone induced reproducible changes in the peaks of differential spectra corresponding to 1.26 ppm, choline/phosphocholine, and glutamate/glutamine. Dexamethasone treatment broadened lipid peaks. Changes after treatment with sodium butyrate were obscure. Microscopically, cells were induced to morphologically different phenotypes by each drug.
  
  
  CONCLUSIONS
  Cells induced to exhibit morphologically different phenotypes present different 1H spectra.
authors.affiliation: Department of Radiology and Nuclear Medicine, Kyoto University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakai
authors.forename: R
authors.initials: R
authors.lastname: Ishima
authors.forename: H
authors.initials: H
authors.lastname: Sakahara
authors.forename: K
authors.initials: K
authors.lastname: Endo
authors.forename: J
authors.initials: J
authors.lastname: Konishi
authors.forename: K
authors.initials: K
authors.lastname: Akasaka
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000503:physiopathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002794:Choline / Q000032:analysis / Q000378:metabolism; D003401:Creatine / Q000032:analysis / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology*; D018698:Glutamic Acid / Q000032:analysis / Q000378:metabolism; D005973:Glutamine / Q000032:analysis / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006859:Hydrogen; D007371:Interferon-gamma / Q000494:pharmacology*; D007773:Lactates / Q000032:analysis / Q000378:metabolism; D008175:Lung Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D009682:Magnetic Resonance Spectroscopy; D010641:Phenotype; D010743:Phospholipids / Q000032:analysis / Q000378:metabolism; D010767:Phosphorylcholine / Q000032:analysis / Q000378:metabolism; D014280:Triglycerides / Q000032:analysis / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D002087:Butyrates; D056572:Histone Deacetylase Inhibitors; D007773:Lactates; D010743:Phospholipids; D014280:Triglycerides; D005973:Glutamine; D010767:Phosphorylcholine; D020148:Butyric Acid; D018698:Glutamic Acid; D003907:Dexamethasone; D006859:Hydrogen; D007371:Interferon-gamma; D003401:Creatine; D002794:Choline